Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes

Figure 1

Characterization of surface marker expressions on NK effector cells and target cell lines using FCM analysis: (a) different expression of CD16 (upper panel) and CD319 (SLAMF7) (lower panel) in the two human NK cell lines, NK-92MI and NK-92MI/CD16a. No significant difference in the MFI of CD319 between the two cell lines (n = 5, right panel), (b) representative results of CD16 (upper panel) and CD319 (lower panel) before (light gray, day 0) and after (dark gray, day 21) expansion of fresh PBMCs from a donor (left panel) and patient (right panel), (c) CD319 (upper panel) and CD279 (PD-1) (lower panel) in target K562, U266, RPMI 8226, and MM.1S cells. Histogram overlay showing representative results for each in comparison to the control. Light gray, isotype control; dark gray, stained with anti-CD16, anti-CD319, or anti-CD279 (a)–(c), and (d) representative result of CD56⁺CD3^– and CD56^–CD3⁺ before (day 0) and after (day 21; left panel) expansion of frozen PBMCs from a donor (upper panel) or patient (lower panel). Each data point represents mean ± SD of CD56⁺CD3^– (solid line) and CD56^–CD3⁺ (dotted line) on eNKs from donors and patients (right panel, day 0 to day 21, n = 3, respectively).

(a)

(b)

(c)

(d)